BioNTech Investor Day Presentation Deck
BNT312
Double-conditional dual-agonist molecule
In the absence of CD40+ cells,
BNT312 does not exhibit any 4-1BB activation
Relative luminescence units
1x106-
8×1054
6x105-
4x105-
2x105-
without 4-1BB* K562 cells
CD40 reporter assay
0 TTT
0.0001 0.001 0.01 0.1
T
T
T
T
1
Antibody concentration (µg/mL)
10
DuoBody-CD40x4-1BB
recombinant CD40L
4x105.
3x105.
2x105-
1×105-
with 4-1BB K562 cells
0
0.0001 0.001 0.01 0.1
▬▬▬▬▬▬▬▬
1
Antibody concentration (µg/mL)
bsAb-CD40xctrl
bsAb-ctrlx4-1BB
Isotype ctrl
BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits.
Muik A, et al. J Immuno Ther Cancer 2022; 10:e004322.
10
Fold increase in luminescence
In the absence of 4-1BB+ cells,
BNT312¹ does not exhibit any CD40 activation
2.0₁
1.5-
1.0-
0.5-
4-1BB reporter assay
without CD40* K562 cells
1
0.001 0.01 0.1
Antibody concentration (µg/mL)
10
DuoBody-CD40x4-1BB
Recombinant 4-1BBL
2.01
1.5-
1.0-
0.5-
Protein therapeutics
with CD40 K562 cells
bsAb-CD40xctrl
bsAb-ctrlx4-1BB
T
0.0001 0.001 0.01 0.1
Antibody concentration (µg/mL)
1
BIONTECH 125View entire presentation